A Dual-Track Knowledge Graph for Evidence-Based Pediatric Medication Management in Neurological Disorders: Implications for Rational Drug Use and Public Health Governance

Children with neurological conditions such as epilepsy, cerebral palsy, or tic disorders often face a difficult reality: the medicines designed to help them are frequently not made for their bodies. Unlike adults, whose nervous systems are fully formed, children are still growing, and their bodies process drugs in unique ways that change as they age. This biological difference means that a treatment safe for an adult might be ineffective or even dangerous for a child. Yet, for decades, doctors have had to rely on fragmented information, often prescribing medications that were never officially tested or approved for pediatric use. This practice, known as off-label prescribing, leaves families and clinicians navigating a maze of uncertainty, where the right dose, the right form of the medicine, and the right safety data are often missing. The goal of modern medicine is to replace this guesswork with clear, evidence-based standards, but gathering those standards has been a monumental task because the necessary information is scattered across thousands of pages of guidelines, regulatory documents, and research papers.

To solve this problem, researchers from China Pharmaceutical University have built a new digital tool called a dual-track knowledge graph. Think of this tool as a massive, organized map that connects diseases to the medicines that treat them, but with a crucial twist: it separates what is definitely known from what is only a promising possibility. The researchers gathered data from forty different clinical practice guidelines published between 2008 and 2025, along with official drug approval records from major regulatory bodies. They then used computer systems to organize this information into two distinct paths. The first path, the primary track, contains only the relationships between diseases and drugs that are explicitly recommended by expert consensus and clinical guidelines. This ensures that the core advice given to doctors is based on the highest level of authority and safety. The second path, the auxiliary track, looks for potential connections that make sense scientifically but have not yet been written into official guidelines. By analyzing the text of medical literature for similarities in symptoms and drug mechanisms, this track identifies medicines that could help children with rare or difficult-to-treat conditions, offering a safe space for exploration without compromising the safety of standard treatments.

The result of this work is a comprehensive system covering thirty-two common pediatric neurological disorders and nearly eight thousand specific drug formulations. Within this system, the researchers identified over fifteen hundred confirmed, guideline-backed relationships between diseases and treatments. These are the solid facts that doctors can rely on for routine care. However, the system also uncovered three thousand three hundred additional, potential treatment options. These are not random guesses; they are carefully filtered suggestions that passed strict safety checks, such as ensuring the drug is not contraindicated for children and that the biological mechanism matches the disease. This dual approach allows the medical community to maintain strict safety standards for common cases while simultaneously keeping an eye on innovative solutions for the most complex and rare conditions that often lack clear treatment protocols.

When the researchers analyzed the data within this new framework, they found significant gaps in the current landscape of pediatric medicine, particularly within domestic resources. The most striking finding was that more than half of the drugs recommended by experts for treating these neurological conditions lack official approval for use in children. This means that for a vast number of treatments, doctors are prescribing medicines that have only been tested on adults, creating a situation where the safety and effectiveness for a child are not guaranteed by regulatory authorities. Furthermore, the study highlighted a severe shortage of child-friendly medicine formats. More than seventy percent of the top-tier treatments are available only in adult-sized tablets or capsules, forcing medical staff to manually cut pills or mix liquids to get the right dose for a small child. This manual process is prone to error and can lead to children receiving too much or too little medicine, which can destabilize their condition or cause harmful side effects.

The analysis also revealed that access to the newest and most effective treatments is uneven. Many advanced, targeted therapies and specialized formulations that are widely used in other countries have not yet received approval for the domestic market. This creates a barrier where children with complex neurological disorders cannot access the most up-to-date care available globally. The researchers noted that while the primary track of their knowledge graph provides a clear path for standard care, the auxiliary track offers a vital lifeline for those rare cases where standard guidelines fall short. For instance, the system identified specific combinations of drugs that could help children with severe epilepsy who also struggle with attention deficits, or rare seizure syndromes that lack a single standard treatment. These findings provide a structured way to explore these options safely, ensuring that even the most difficult cases have a reference point for potential improvement.

Ultimately, this study demonstrates that organizing medical knowledge into a structured, dual-track system can reveal both the strengths and the weaknesses of current healthcare resources. It confirms that while there is a strong foundation of expert consensus for many common conditions, the system is failing children in three critical areas: the lack of official pediatric approvals for necessary drugs, the scarcity of medicines designed specifically for children's bodies, and the unequal access to global medical advancements. By making these gaps visible and quantifiable, the researchers hope to guide policymakers and pharmaceutical companies toward filling these voids. The framework does not just list problems; it offers a method to manage the evidence, ensuring that every decision about a child's medication is backed by the best available data, whether that data comes from a long-established guideline or a carefully vetted new discovery. This approach moves the field away from scattered, inconsistent practices toward a future where pediatric neurological care is standardized, safe, and accessible for every child.